Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORAL-28Generic

ORTHO TRI-CYCLEN LO

ETHINYL ESTRADIOL; NORGESTIMATE

Standard Dose
0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ORTHO TRI-CYCLEN LO is listed in Drugs@FDA under application 021241 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORGESTIMATE Form and strength TABLET;ORAL-28 - 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2017-08-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview ORTHO TRI-CYCLEN LO is listed in Drugs@FDA under application 021241 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ETHINYL ESTRADIOL; NORGESTIMATE Form and strength TABLET;ORAL-28 - 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2017-08-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ORTHO TRI-CYCLEN LO (ETHINYL ESTRADIOL; NORGESTIMATE) | Drug Monograph | MedicHelpline